Cardiac Insight said today it launched its Cardea Solo electrocardiogram sensor designed for diagnosing atrial fibrillation following cardiac ablation.
The Cardea Solo device is designed to provide both physicians and patients with cardiac data and help diagnose a variety of arrhythmias including atrial fibrillation, the Kirkland, Wash.-based company said.
The Cardea Solo sensor is a lightweight, leadless, water resistant single-use disposable designed to record ECG data and patient symptoms. The device can be worn under clothing for up to 7 days, the company said.
“Cardiac Insight’s Cardea Solo is a game changer in the cardiac med-device market. Cardea Solo is an off-the-shelf product. It is not a service; so there is no lag time due to enrollment with a tech or third-party service company. The device offers physicians immediate access to improved reporting and analysis of heartbeat-to-heartbeat data. The design and ease-of-use also makes it more likely patients will wear the sensor and capture meaningful data for enhanced evaluation,” co-founder & CEO Brad Harlow said in a press release.
Cardiac Insight touts the Cardea Solo sensor as the 1st and only wearable cardiac sensor which which does not require a 3rd-party service centers to transmit or analyze data, instead providing it to the individual’s physician and staff.
“It is vital to detect and treat atrial fibrillation before it causes a stroke or heart failure. Cardea Solo provides the information doctors need in a more timely and cost-effective manner than currently offered by other wearable sensors,” former Heart Rhythm Society prez Dr. Robert Hauser of the Minneapolis Heart Institute said in a prepared statement.
Cardiac Insight won FDA 510(k) clearance for the Cardea Solo ECG sensor in April.